Улипристала ацетат в лечении миомы матки. Как медикаментозное лечение меняет существующие парадигмы?

Обложка

Цитировать

Полный текст

Аннотация

В статье представлены современные данные о механизмах влияния селективного модулятора прогестероновых рецепторов - улипристала ацетат на миоматозные узлы и его роли в лечении миомы матки. Освещены вопросы эффективности и безопасности применения, а также репродуктивные исходы терапии.

Об авторах

Наталия Михайловна Подзолкова

ФГБОУ ДПО РМАНПО

Email: podzolkova@gmail.com
д-р мед. наук, проф., зав. каф. акушерства и гинекологии Moscow, Russia

Вера Вячеславовна Коренная

ФГБОУ ДПО РМАНПО

Email: drkorennaya@mail.ru
канд. мед. наук, доц. каф. акушерства и гинекологии Moscow, Russia

Роман Эдуардович Кузнецов

ФГБОУ ДПО РМАНПО

д-р мед. наук, проф. каф. акушерства и гинекологии Moscow, Russia

Ольга Юрьевна Игнатченко

ГБУЗ «ГКБ им. С.П. Боткина»

зав. отд. гинекологии Moscow, Russia

Список литературы

  1. Ahrendt H.J, Tylkoski H, Rabe T et al. Prevalence of uterine myomas in women in Germany: data of an epidemiological study. Arch Gynecol Obstet 2016; 293 (6): 1243-53.
  2. Merrill R.M. Hysterectomy surveillance in the United States, 1997 through 2005. Med Sci Monit 2008; 14 (1): CR24-31.
  3. Whiteman M.K, Hillis S.D, Jamieson D.J et al. Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol 2008; 198 (1): 34.e1-7.
  4. Buie V.C, Owings M.F, DeFrances C.J, Golosinskly A. National Hospital Discharge Survey: 2006 summary. National Center for Health Statistics. 2010. Available at: www.cdc.gov/nchs/data/series/sr_13/sr13_168.pdf
  5. Howard B.V, Kuller L, Langer R et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Womens Health Initiative Observational Study. Circulation 2005; 111 (12): 1462-70.
  6. Phung T.K, Waltoft B.L, Laursen T.M et al. Hysterectomy, oophorectomy and risk of dementia: a nationwide historical cohort study. Dement Geriatr Cogn Dis 2010; 30 (1): 43-50.
  7. Read M.D, Edey K.A, Hapeshi J, Foy C. The age of ovarian failure following premenopausal hysterectomy with ovarian conservation. Menopause Int 2010; 16 (2): 56-9.
  8. Ingelsson E, Lundholm C, Johansson A.L, Altman D. Hysterectomy and risk of cardiovascular disease: a population-based cohort study. Eur Heart J 2011; 32 (6): 745-50.
  9. Melton L.J, Achenbach S.J, Gebhart J.B et al. Influence of hysterectomy on long-term fracture risk. Fertil Steril 2007; 88 (1): 156-62.
  10. Blandon R.E, Bharucha A.E, Melton L.J et al. Incidence of pelvic floor repair after hysterectomy: a population-based cohort study. Am J Obstet Gynecol 2007; 197 (6): 664, e1-e7.
  11. Rocca W.A, Bower J.H, Maraganore D.M et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007; 69 (11): 1074-83.
  12. Rocca W.A, Grossardt B.R, Geda Y.E et al. Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause 2008; 15 (6): 1050-9.
  13. Rocca W.A, Bower J.H, Maraganore D.M et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008; 70 (3): 200-9.
  14. Altman D, Yin L, Johansson A et al. After Hysterectomy. Arch Intern Med 2010; 170 (22): 2011-6. doi: 10.1001/archinternmed.2010.425
  15. Chan C.C, Ng E.H, Ho P.C. Ovarian changes after abdominal hysterectomy for benign conditions. J Soc Gynecol Invest 2005; 12 (1): 54-7.
  16. Farquhar C.M, Sadler L, Harvey S.A, Stewart A.W. The association of hysterectomy and menopause: a prospective cohort study. BJOG 2005; 112 (7): 956-62.
  17. Moorman P.G, Myers E.R, Schildkraut J.M et al. Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynecol 2011; 118 (6): 1271-9.
  18. Parker W.H, Broder M.S, Liu Z et al. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005; 106 (2): 219-26.
  19. Rocca W.A, Ulrich L.G. Oophorectomy for whom and at what age? Primum non nocere. Maturitas 2012; 71 (1): 1-2.
  20. Лебедев В.А., Давыдов А.И., Пашков В.М. Спорные и нерешенные вопросы лечения и профилактики миомы матки у больных репродуктивного периода. Трудный пациент. 2013. @@Lebedev V.A., Davydov A.I., Pashkov V.M. Spornye i nereshennye voprosy lecheniia i profilaktiki miomy matki u bol'nykh reproduktivnogo perioda. Trudnyi patsient. 2013 (in Russian)
  21. Ариничева А.B. Влияние эмболизации маточных артерий на функциональное состояние яичников и эндомиометрия у женщин репродуктивного возраста с миомой матки. Дис. … канд. мед. наук. Барнаул, 2006.@@Arinicheva A.B. The effect of uterine artery embolization on the functional state of the ovaries and endomyometry in women of reproductive age with uterine myoma. Dis. … kand. med. nauk. Barnaul, 2006 (in Russian)
  22. Van der Kooij S.M, Bipat S, Hehenkamp W.J et al. Uterine artery embolization versus surgery in the treatment of symptomatic fibroids: a systematic review and metaanalysis. Am J Obstet Gynecol 2011; 205 (4): 317.e1-18.
  23. Hehenkamp W.J., Volkers N.A, Broekmans F.J et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod 2007; 22 (7): 1996-2005.
  24. Stewart E.A, Rabinovici J, Tempany C.M et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril 2006; 85 (1): 22-9.
  25. Gorny K.R, Woodrum D.A, Brown D.L et al. Magnetic resonance-guided focused ultrasound of uterine leiomyomas: review of a 12-month outcome of 130 clinical patients. J Vasc Interv Radiol 2011; 22 (6): 857-64.
  26. Bouchard P, Chabbert-Buffet N, Fauser B.C.J.M. Selective progesterone receptor modulators in reproductive medicine: Pharmacology, clinical efficacy and safety. Fertil Steril 2011; 96 (5): 1175-89. doi: 10.1016/j.fertnstert.2011.08.021
  27. Коренная В.В., Подзолкова Н.М. Улипристала ацетат в лечении миомы матки. Гинекология. 2013; 15 (6): 58-61. @@Korennaia V.V., Podzolkova N.M. Ulipristala atsetat v lechenii miomy matki. Gynecology. 2013; 15 (6): 58-61 (in Russian)
  28. Courtoy G.E, Henriet P, Marbaix E et al. Matrix Metalloproteinase Activity Correlates With Uterine Myoma Volume Reduction After Ulipristal Acetate Treatment. J Clin Endocrinol Metab 2018; 103 (4): 1566-73. doi: 10.1210/jc.2017-02295
  29. Courtoy G.E, Donnez J, Ambroise J et al. Gene expression changes in uterine myomas in response to ulipristal acetate treatment. Reprod Biomed Online 2018; 37 (2): 224-33. doi: 10.1016/j.rbmo.2018.04.050
  30. Raga F, Pascual C, Boigues D. Cystic degeneration of uterine leiomyoma during ulipristal acetate treatment. Uterus Ovary 2016; 2: e1077.
  31. Donnez J, Courtoy G.E, Donnez O, Dolmans M. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review. Reprod BioMed Online 2018; 37: 216-23.
  32. Donnez J, Arriagada P, Donnez O, Dolmans M.M. Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators. Curr Opin Obstet Gynecol 2015; 27: 422-31.
  33. Woodhead N, Pounds R, Irani S, Pradhan P. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital. J Obstet Gynaecol 2018; 38 (6): 813-7. doi: 10.1080/01443615.2017.1405926
  34. Simon J.A, Catherino W, Blakesley R. Ulipristal acetate treatment of uterine fibroids in black and obese women: VENUS I subgroup analyses [28G]. Obstet Gynecol 2017; 129: 78S-79S.
  35. Simon J, Catherino W.H, Segars J. First US-based phase 3 study of ulipristal acetate (UPA) for symptomatic uterine fibroids (UF): results of VENUS-I. Fertil Steril 2016; 106 (3): e376.
  36. Malone L.J. Myomectomy: recur ence after removal of solitary and multiple myomas. Obstet Gynecol 1969; 34 (2): 200-3.
  37. Peddada S.D, Laughlin S.K, Miner K. Growth of uterine leiomyomata among premenopausal black and white women. Proc Nat Acad Sci U S A 2008.
  38. Murji A, Crosier R, Chow T. Role of ethnicity in treating uterine fibroids with ulipristal acetate. Fertil Steril 2016; 106 (5): 1165-9.
  39. Lee M.J, Yun B.S, Seong S.J. Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist. Obstet Gynecol Sci 2017; 60 (1): 69-73.
  40. Mutter G.L, Bergeron C, Deligdisch L. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21 (5): 591-8.
  41. Laursen J.B, Istre O. Unexpected uterine leiomyosarcoma during laparoscopic hysterectomy. J Gynecol Surg 2016; 32 (5): 280-5.
  42. Donnez J, Donnez O, Matule D et al. Longterm medical management of uterine fibroids with ulipristal acetate. Fertil Steril 2016; 105: 165-73.e4.
  43. PRAC recommends new measures to minimize risk of rare but serious liver injury with Esmya for fibroids. Regular liver function testing required during treatment EMA/289137/2018 18 May 2018. http: //www.ema.europa.eu/
  44. Donnez J, Vázquez F, Tomaszewski J et al. PEARL III and PEARL III Extension Study Group, 2014. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014; 101: 1565-73.e1-18.
  45. Donnez J, Tomaszewski J, Vázquez F et al. PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366: 421-32.
  46. Donnez J, Hudecek R, Donnez O et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 2015; 103: 519-27.e3.
  47. Donnez J, Donnez O, Dolmans M.M. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Expert Opin Drug Saf 2016; 15: 1679-86.
  48. Luyckx M, Squifflet J.L, Jadoul P. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril 2014; 102 (5): 1404-9.
  49. Hrgovic Z, Habek D, Cerkez Habek J et al. Spontaneous pregnancy during ulipristal acetate treatment of giant uterine leiomyoma. J Clin Pharm Ther 2018; 43: 121-3.
  50. Bizzarri N, Ghirardi V, Remorgida V. Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study. Eur J Obstet Gynecol Reprod Biol 2015; 192: 22-6.
  51. Ferrero S, Racca A, Tafi E. Ulipristal acetate before high complexity hysteroscopic myomectomy: a retrospective comparative study. J Minim Invasive Gynecol 2016; 23 (3): 390-5.
  52. Ferrero S, Alessandri F, Vellone V.G. Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study. Eur J Obstet Gynecol Reprod Biol 2016; 205: 43-7.
  53. Aref-Adib M, Oliver R, Odejinmi F. Esmya and its effects: laparoscopic myomectomy after using ulipristal acetate. Gynecol Surg 2016; 13 (3): 215-80.
  54. Wais M, Lee S, Liu G. Surgical experience with ulipristal acetate or gonadotropin releasing hormone agonists for uterine fibroids. J Minim Invasive Gynecol 2016; 23 (7): S1-S252.
  55. Fernandez H, Schmidt T, Powell M et al. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: premya study results. Eur J Obstet Gynecol Reprod Biol 2017; 208: 91-6.
  56. Murji A, Whitaker L, Chow T.L. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev 2017; 4: CD010770.
  57. Odejinmi F, Huff K.O, Oliver R. Individualisation of intervention for tubal ectopic pregnancy: historical perspectives and the modern evidence based management of ectopic pregnancy. Eur J Obstet Gynecol Reprod Biol 2017; 210: 69-75.
  58. Czuczwar P, Wozniak S, Szkodziak P. Influence of ulipristal acetate therapy compared with uterine artery embolization on fibroid volume and vascularity indices assessed by three-dimensional ultrasound: prospective observational study. Ultrasound Obstet Gynecol 2015; 45 (6): 744-50.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2019

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).